During the Union Budget 2025-26, Finance Minister Nirmala Sitharaman announced that the government will promote medical tourism and will ease visa process under the “Heal in India” initiative.
She also proposed adding 36 drugs for cancer, rare diseases to be exempt from Basic customs duty (BSD). The FM also announced plans to launch 200 cancer daycare centres which will be set up in government hospitals within the next 3 years in all districts.
She also announced Specified drugs and medicines under a patient assistance program run by the pharmaceutical companies are fully exempt from BCD provided if medicines are supplied free of cost to the patients. She also proposed to add 37 more medicines along with 13 new patient assistance programmes.
The stocks that will benefit
Astrazeneca Pharma
AstraZeneca Pharma India, established in 1979, manufactures, distributes, and markets pharmaceutical products, while also coordinating clinical trial services with its global parent company. The company focuses on key therapeutic areas such as oncology, cardiology, metabolism, diabetes, respiratory, and renal. Headquartered in Cambridge, UK, AstraZeneca operates in over 100 countries worldwide.
The shares of Astrazeneca pharma reached an intraday high of Rs 7545 per share, around 4% higher than its previous close of Rs 7,235.
Wockpharma
Wockhardt Limited is a global pharmaceutical and biotechnology company dedicated to providing affordable, high-quality medicines. It focuses on key areas like antibiotics, diabetes, vaccines, and biotechnology products. With a strong commitment to innovation, Wockhardt continues to expand its global portfolio of medicines for a healthier world.
The shares of Wockpharma reached an intraday high of Rs 1,530 per share, around 7.4% higher than its previous close of Rs 1,417 per share.
Krsnaa Diagnostics
The company provides diagnostic services across India, offering radiology and pathology services, including X-ray, CT scan, MRI, mammography, and blood/urine tests. It has served over 40 million patients in the last 3 years across 18 states and UTs, with 121 processing labs, 3,139 collection centers, and 178 CT/MRI centers.
The shares of Krsnaa Diagnostics reached an intraday high of Rs 888 per share, around 5% higher than the previous close of Rs 845 per share.
Beta drugs
Beta Drugs, a part of Adley Group is an Indian-based company that is engaged in the business of manufacturing oncology medicines. It offers a wide range of oncology products with their portfolio consisting of around 50 products catering to various oncology diseases.
The shares of Beta Drugs reached an intraday high of Rs 1,999 per share, around 6% higher than the previous close of Rs 1,884.
Written By Adhvaitha Nayani
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Pharma stocks in focus after 36 life-saving drugs to be fully exempt from basic customs duty appeared first on Trade Brains.